Identifying cancer risk in patients with Barrett's esophagus using a new test
Stratification of Cancer Risk in Patients with Non-Dysplastic Barrett's Esophagus using TissueCypher: The SCRiBE study
This study is looking at how to better spot patients with Barrett's esophagus who might be at risk for developing esophageal cancer, using a special test on biopsy samples to find early signs of trouble, so we can help manage their health more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor Research Institute NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11114067 on NIH RePORTER |
What this research studies
This research focuses on Barrett's esophagus, a condition that can lead to esophageal cancer, and aims to improve how we identify patients at risk for developing this cancer. The study utilizes the TissueCypher BE Assay, which analyzes biopsy samples to detect early molecular changes that indicate a higher risk of cancer, even in patients without dysplasia. By refining the screening process, the research seeks to provide a more effective way to monitor and manage Barrett's esophagus patients, potentially leading to better outcomes. Patients will be evaluated through endoscopic procedures and their biopsy results will inform their risk level for cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Barrett's esophagus, particularly those who have a history of gastroesophageal reflux disease.
Not a fit: Patients who do not have Barrett's esophagus or those with other unrelated esophageal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate risk assessments for patients with Barrett's esophagus, allowing for timely interventions and potentially reducing the incidence of esophageal cancer.
How similar studies have performed: Previous studies have shown that similar approaches using the TissueCypher assay have successfully identified patients at varying risk levels for cancer progression.
Where this research is happening
Dallas, United States
- Baylor Research Institute — Dallas, United States (Active)
Researchers
- Principal investigator: Souza, Rhonda F — Baylor Research Institute
- Study coordinator: Souza, Rhonda F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.